Orchid Pharma Shares Surge on Landmark Russia Licensing Deal for Novel Antibiotic Exblifep

’s shares surged nearly 9-11% after the company signed a licensing and supply agreement with Russia’s Pharmasyntez JSC for its novel antibiotic Exblifep (cefepime/enmetazobactam). Under the pact, Pharmasyntez gains exclusive rights to register and commercialize the drug in Russia for complicated urinary tract infections (cUTI) and hospital-acquired/ventilator-associated pneumonia (HAP/VAP), subject to regulatory approval. Orchid will supply the finished dosage form. The deal taps into a potential USD 178 million opportunity over 10 years, addressing rising antimicrobial resistance in Gram-negative infections. Exblifep, already approved in the US and EU, strengthens Orchid Pharma’s global footprint in the antibiotics segment.